FI112077B - Uusi kiteinen paroksetiinimetaanisulfonaatti ja sitä sisältävä farmaseuttinen koostumus - Google Patents

Uusi kiteinen paroksetiinimetaanisulfonaatti ja sitä sisältävä farmaseuttinen koostumus Download PDF

Info

Publication number
FI112077B
FI112077B FI990922A FI990922A FI112077B FI 112077 B FI112077 B FI 112077B FI 990922 A FI990922 A FI 990922A FI 990922 A FI990922 A FI 990922A FI 112077 B FI112077 B FI 112077B
Authority
FI
Finland
Prior art keywords
paroxetine
solution
paroxetine methanesulfonate
methanesulfonate
crystalline
Prior art date
Application number
FI990922A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI990922A (fi
FI990922A0 (fi
Inventor
Neal Ward
Andrew Simon Craig
Deirdre O'keeffe
Alan David Jones
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112077(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of FI990922A0 publication Critical patent/FI990922A0/fi
Publication of FI990922A publication Critical patent/FI990922A/fi
Application granted granted Critical
Publication of FI112077B publication Critical patent/FI112077B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI990922A 1998-07-02 1999-04-23 Uusi kiteinen paroksetiinimetaanisulfonaatti ja sitä sisältävä farmaseuttinen koostumus FI112077B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9814316 1998-07-02
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GB9821732 1998-10-06
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GB9902935 1999-02-10
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (3)

Publication Number Publication Date
FI990922A0 FI990922A0 (fi) 1999-04-23
FI990922A FI990922A (fi) 2000-01-03
FI112077B true FI112077B (fi) 2003-10-31

Family

ID=27269380

Family Applications (2)

Application Number Title Priority Date Filing Date
FI990190U FI4209U1 (fi) 1998-07-02 1999-04-23 Uusia yhdisteitä
FI990922A FI112077B (fi) 1998-07-02 1999-04-23 Uusi kiteinen paroksetiinimetaanisulfonaatti ja sitä sisältävä farmaseuttinen koostumus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI990190U FI4209U1 (fi) 1998-07-02 1999-04-23 Uusia yhdisteitä

Country Status (35)

Country Link
US (4) US6063927A (he)
EP (5) EP1089996B1 (he)
JP (1) JP2002519422A (he)
KR (1) KR20010053336A (he)
CN (1) CN1127502C (he)
AR (2) AR011759A1 (he)
AT (4) AT3185U3 (he)
AU (4) AU732211C (he)
BE (3) BE1011664A6 (he)
BR (1) BR9911682A (he)
CA (1) CA2269999A1 (he)
CH (1) CH689805A8 (he)
DE (5) DE69900007T2 (he)
DK (7) DK199900176U3 (he)
ES (4) ES2149044T3 (he)
FI (2) FI4209U1 (he)
FR (2) FR2780728B1 (he)
GB (5) GB2336364B (he)
GR (3) GR990100140A (he)
HK (1) HK1037877A1 (he)
HU (1) HUP0102334A3 (he)
IE (5) IE990344A1 (he)
IL (1) IL140628A (he)
IT (1) IT1312540B1 (he)
LU (1) LU90388B1 (he)
NL (4) NL1011874C1 (he)
NO (1) NO319030B1 (he)
NZ (1) NZ509180A (he)
PL (1) PL345214A1 (he)
PT (4) PT1089996E (he)
SE (1) SE9901462A0 (he)
SI (3) SI1089996T1 (he)
SK (1) SK20262000A3 (he)
TR (1) TR200100054T2 (he)
WO (1) WO2000001694A1 (he)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
KR100462423B1 (ko) * 1997-02-27 2004-12-17 아지노모토 가부시키가이샤 정석 장치 및 정석 방법
EP1078925A1 (en) * 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
JP2004507504A (ja) * 2000-08-28 2004-03-11 シントン・ベスローテン・フェンノートシャップ パロキセチン組成物およびその製造方法
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
CA2456233A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
EP1778183B1 (en) * 2004-08-18 2018-06-27 Synthon B.V. Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
US20090054529A1 (en) * 2005-04-07 2009-02-26 Xy, Inc. Flow Path Conditioner System
AU2006315684A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
KR20090118110A (ko) * 2007-03-09 2009-11-17 노파르티스 아게 3-(1ｈ-인돌-3-일)-4-[2-(4-메틸-피페라진-1-일)-퀴나졸린-4-일]-피롤-2,5-디온의 염
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) * 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (he) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223430B1 (en) * 1985-10-21 1991-02-27 Honda Giken Kogyo Kabushiki Kaisha Method for controlling the solenoid current of a solenoid valve which controls the amount of suction of air in an internal combustion engine
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
CA2216934A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
AU721257B2 (en) * 1995-05-17 2000-06-29 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP3081250B2 (ja) * 1995-10-31 2000-08-28 メルク エンド カンパニー インコーポレーテッド 置換アゼチジノンの製造方法
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Process for drying paroxetine hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
EP1078925A1 (en) * 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
KR20010040711A (ko) * 1998-02-06 2001-05-15 피터 기딩스 파록세틴의 염
AP2000001907A0 (en) * 1998-03-16 2000-09-30 Smithkline Beecham Plc Crystalline form of paroxetine.
HUP0103651A3 (en) * 1998-04-09 2002-12-28 Smithkline Beecham Plc Paroxetine maleate and process for its preparation
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
FI990922A (fi) 2000-01-03
FR2802098A1 (fr) 2001-06-15
IES20000894A2 (en) 2001-05-30
PL345214A1 (en) 2001-12-03
EP0970955A1 (en) 2000-01-12
GR3034328T3 (en) 2000-12-29
US20020193406A1 (en) 2002-12-19
GB2367003A (en) 2002-03-27
AR018197A1 (es) 2001-10-31
KR20010053336A (ko) 2001-06-25
IES990343A2 (en) 2000-01-02
US20020035130A1 (en) 2002-03-21
AT3185U3 (de) 2000-01-25
BE1012403A5 (fr) 2000-10-03
EP1288214A1 (en) 2003-03-05
ES2149044T3 (es) 2000-10-16
FIU990190U0 (fi) 1999-04-23
GB2336364B (en) 2000-05-10
US6063927A (en) 2000-05-16
IE20000633A1 (en) 2001-10-17
DE60000003D1 (de) 2001-08-09
IL140628A0 (en) 2002-02-10
HK1037877A1 (en) 2002-02-22
IL140628A (he) 2004-06-20
EP1020464A1 (en) 2000-07-19
CN1315949A (zh) 2001-10-03
ATE251155T1 (de) 2003-10-15
GB2336364A (en) 1999-10-20
IES20000893A2 (en) 2001-05-30
GB2377637A (en) 2003-01-22
DK1089996T3 (da) 2004-02-09
ES2209428T3 (es) 2004-06-16
PT970955E (pt) 2000-11-30
ITMI990866A1 (it) 2000-10-23
DE69911774D1 (de) 2003-11-06
DK0970955T3 (da) 2000-10-09
IE990344A1 (en) 2000-05-03
FI4209U1 (fi) 1999-11-10
GR990100140A (el) 2000-03-31
AU713131B3 (en) 1999-11-25
GB2339428A (en) 2000-01-26
NL1011875C2 (nl) 2000-03-24
ES2157881T3 (es) 2001-09-01
PT102291A (pt) 2000-05-31
EP1089996B1 (en) 2003-10-01
ES2158778B1 (es) 2002-03-16
SE9901462L (he)
SI0970955T1 (en) 2001-02-28
NL1011875A1 (nl) 2000-01-07
AU3619199A (en) 2000-01-24
HUP0102334A3 (en) 2003-12-29
CH689805A5 (fr) 1999-11-30
SI1020464T1 (en) 2001-12-31
JP2002519422A (ja) 2002-07-02
NL1011874C1 (nl) 1999-07-12
AU732211B2 (en) 2001-04-12
ATE202777T1 (de) 2001-07-15
AU732211C (en) 2004-05-06
GB9920332D0 (en) 1999-11-03
EP0970955B1 (en) 2000-08-02
DK199900234U4 (da) 2000-12-22
SK20262000A3 (sk) 2001-07-10
DK199900554A (da) 2000-01-03
WO2000001694A1 (en) 2000-01-13
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
AT3185U2 (de) 1999-11-25
HUP0102334A2 (hu) 2002-05-29
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
FR2780728B1 (fr) 2001-02-16
ATE195121T1 (de) 2000-08-15
CN1127502C (zh) 2003-11-12
BR9911682A (pt) 2001-12-26
DE29907248U1 (de) 1999-09-09
DK199900234U1 (da) 2000-12-22
FR2780728A1 (fr) 2000-01-07
GR1003350B (el) 2000-03-29
AR011759A1 (es) 2000-09-13
AU2392899A (en) 2000-01-20
SE9901462A0 (sv) 2000-01-03
NO991944L (no) 2000-01-03
NL1012272C1 (nl) 1999-07-12
GB0026487D0 (en) 2000-12-13
NZ509180A (en) 2001-06-29
DK200000390U1 (da) 2000-12-27
DE69900007D1 (de) 2000-09-07
IT1312540B1 (it) 2002-04-22
GB2352395B (en) 2004-02-11
NO319030B1 (no) 2005-06-06
DK1020464T3 (da) 2001-09-24
LU90388B1 (fr) 2001-01-29
EP1020464B1 (en) 2001-07-04
DE69900007T2 (de) 2001-06-07
DE60000003T2 (de) 2002-03-21
US20010023253A1 (en) 2001-09-20
FI990922A0 (fi) 1999-04-23
CH689805A8 (fr) 2000-02-29
GR3036208T3 (en) 2001-10-31
DE69911774T2 (de) 2004-08-05
SI1089996T1 (en) 2004-04-30
IES81166B2 (en) 2000-05-31
CA2269999A1 (en) 2000-01-02
ES2158778A1 (es) 2001-09-01
PT1020464E (pt) 2001-10-30
PT102291B (pt) 2002-07-31
SE9901462D0 (sv) 1999-04-23
EP1020463A1 (en) 2000-07-19
GB9909505D0 (en) 1999-06-23
EP1089996A1 (en) 2001-04-11
NL1012271C2 (nl) 1999-09-23
DE19918588A1 (de) 2000-01-27
DK199900176U3 (da) 1999-08-13
BE1011664A6 (fr) 1999-11-09
TR200100054T2 (tr) 2001-06-21
AU713877B3 (en) 1999-12-09
BE1012420A6 (fr) 2000-10-03
NO991944D0 (no) 1999-04-23
GB2352395A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
FI112077B (fi) Uusi kiteinen paroksetiinimetaanisulfonaatti ja sitä sisältävä farmaseuttinen koostumus
AU2002100370A4 (en) Novel compound
AU724845B3 (en) Novel compound
AU2001100025A4 (en) Novel compound
AU732558B3 (en) Novel compound
MXPA01000307A (en) Paroxetine methanesulfonate
CZ20004924A3 (cs) Methansulfonat paroxetinu
IES83541Y1 (en) Paroxetine methanesulfonate
AU5430701A (en) Novel compound